- We'll take a look at an interesting therapeutic idea involving T-cells and how it's going.
- For some years now, Amgen has been working on a technology called "BiTE", which stands for "bispecific T-cell engager". It fits into the general "bifunctional molecule" idea that's so popular these days.
- One of the ways that Amgen has been trying to improve their BiTE molecules is through improving their half-lives. They've been working on one of those (pavurutamab, AMG 701) that brings in T cells as before via CD3 and also targets the B-cell maturation antigen protein (BCMA) to treat multiple myeloma.
- But not all of those will be Amgen's, nor will all the successes. I haven't even mentioned another parallel effort from MacroGenics, their "DART" (dual affinity re-targeting) platform and their "TRIDENT" one that brings in a third protein.
For further details see:
T Cells (And Bifunctionals) For Everything